Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 92 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 0.4 mo · strongest signal: Exchange deficiency notice (Sep 18, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 814 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 18, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-09-18 (accepted 16:05 ET) filing | 60 |
| Sep 18, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-09-18 filing | 58 |
| Sep 18, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-18 filing | 48 |
| Sep 18, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-09-18 filing | 47 |
| Sep 14, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-09-14 filing | 40 |
| Sep 14, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-09-14 (accepted 16:05 ET) filing | 31 |
| Sep 8, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-09-08; 3 prior 424B filings in 12m filing | 27 |
| Sep 4, 2026 | ▼ Shelf effective | EFFECT notice 2026-09-04 filing | 21 |
| Aug 24, 2026 | ▼ Shelf filed | S-1 filed 2026-08-24 filing | 35 |
| Jun 30, 2024 | ▼ Runway < 6 months | ~0.4 months runway: liquidity $306,811 as of 2024-06-30, burn $9,262,090/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 38 |
| Jun 30, 2024 | ▼ Negative equity | Stockholders' equity $-18,827,124 as of 2026-06-30 filing | 31 |
| Jun 30, 2024 | ▼ Cash < current liabilities | Liquidity $306,811 vs current liabilities $31,299,028 filing | 22 |
DAIC CID Holdco, Inc. · SDST Stardust Power Inc. · ISPC iSpecimen Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · BRTX BioRestorative Therapies, In · screener →